LYL 797
Alternative Names: LYL-797Latest Information Update: 03 Jul 2024
At a glance
- Originator Lyell Immunopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 26 Jun 2024 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Triple negative breast cancer released by Lyell Immunopharma
- 24 May 2022 3668626- NCT05274451 trial initiated FE completed INtro devT KDM updated
- 08 Apr 2022 Lyell Immunopharma plans a phase I trial in Breast cancer and Non-small cell lug cancer (Second-line therapy or greater) in 2022 (NCT05274451)